Letter | Published:

Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle

Nature Biotechnology volume 28, pages 7982 (2010) | Download Citation

Subjects

Abstract

Reengineering the receptor footprints of adeno-associated virus (AAV) isolates may yield variants with improved properties for clinical applications. We generated a panel of synthetic AAV2 vectors by replacing a hexapeptide sequence in a previously identified heparan sulfate receptor footprint with corresponding residues from other AAV strains. This approach yielded several chimeric capsids displaying systemic tropism after intravenous administration in mice. Of particular interest, an AAV2/AAV8 chimera designated AAV2i8 displayed an altered antigenic profile, readily traversed the blood vasculature, and selectively transduced cardiac and whole-body skeletal muscle tissues with high efficiency. Unlike other AAV serotypes, which are preferentially sequestered in the liver, AAV2i8 showed markedly reduced hepatic tropism. These features of AAV2i8 suggest that it is well suited to translational studies in gene therapy of musculoskeletal disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Protein Data Bank

References

  1. 1.

    et al. Hemagglutinin receptor binding avidity drives Influenza A virus antigenic drift. Science 326, 734–736 (2009).

  2. 2.

    et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 324, 55–59 (2009).

  3. 3.

    , & New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285–297 (2005).

  4. 4.

    , , & Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008).

  5. 5.

    et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45–53 (2006).

  6. 6.

    et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321–328 (2005).

  7. 7.

    et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther. 15, 1489–1499 (2008).

  8. 8.

    et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457–1467 (2007).

  9. 9.

    et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410 (2002).

  10. 10.

    et al. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072–11081 (2003).

  11. 11.

    , , & Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995–7006 (2003).

  12. 12.

    et al. Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J. Struct. Biol. 165, 146–156 (2009).

  13. 13.

    & Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 158, 182–187 (2007).

  14. 14.

    et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 81, 12260–12271 (2007).

  15. 15.

    et al. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80, 11393–11397 (2006).

  16. 16.

    et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70, 70–78 (2006).

  17. 17.

    et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 15, 12–17 (2008).

  18. 18.

    et al. A myocardium-tropic AAV evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. USA 106, 3946–3951 (2009).

  19. 19.

    et al. A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol. Ther. 10, 386–398 (2004).

  20. 20.

    et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828–834 (2004).

  21. 21.

    et al. Production and characterization of AAV vectors. Nat. Protoc. 1, 1412–1428 (2006).

Download references

Acknowledgements

We would like to thank the American Heart Association (A.A.; no. 0735637N); National Institute of Arthritis and Musculoskeletal and Skin Diseases (A.A. & R.J.S.; R21AR055712); National Institute of Allergy and Infectious Diseases (R.J.S. and A.A.; R01AI072176); National Heart, Lung, and Blood Institute (A.A.; R01HL089221); Senator Paul Wellstone Center for Muscular Dystrophy (R.J.S.; U54AR056953); National Institute of General Medical Sciences (M.A.-M.; R01GM082946); and Asklepios Biopharmaceutical for research support. We would also like to MirusBio Corp. for assistance with isolated limb perfusion studies.

Author information

Affiliations

  1. Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

    • Aravind Asokan
    • , Julia C Conway
    • , Jana L Phillips
    • , Chengwen Li
    • , Rebecca Sinnott
    • , Swati Yadav
    • , Nina DiPrimio
    •  & R Jude Samulski
  2. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

    • Aravind Asokan
  3. Macromolecular Structure Group, University of Florida, Gainesville, Florida, USA.

    • Hyun-Joo Nam
    •  & Mavis Agbandje-McKenna
  4. Mirus BioCorporation, Madison, Wisconsin, USA.

    • Julia Hegge
    •  & Jon Wolff
  5. Asklepios Biopharmaceutical, Inc., Chapel Hill, North Carolina, USA.

    • Scott McPhee

Authors

  1. Search for Aravind Asokan in:

  2. Search for Julia C Conway in:

  3. Search for Jana L Phillips in:

  4. Search for Chengwen Li in:

  5. Search for Julia Hegge in:

  6. Search for Rebecca Sinnott in:

  7. Search for Swati Yadav in:

  8. Search for Nina DiPrimio in:

  9. Search for Hyun-Joo Nam in:

  10. Search for Mavis Agbandje-McKenna in:

  11. Search for Scott McPhee in:

  12. Search for Jon Wolff in:

  13. Search for R Jude Samulski in:

Contributions

A.A. conceived the strategy, designed the project and analyzed data. A.A., S.M. and R.J.S. supervised the project and prepared the manuscript. J.C.C. and R.S. built capsid mutants, J.L.P. and C.L. carried out animal experiments, and J.H., S.M. and J.W. designed and carried out isolated limb perfusion studies. S.Y. carried out Q-PCR studies and N.D., H.-J.N. and M.A.-M. carried out molecular modeling studies.

Competing interests

R.J.S. is the scientific founder and CEO of Asklepios Biopharmaceutical, Inc. J.W. is the scientific founder and CEO of Mirus BioCorporation. A.A. and R.J.S. are inventors on patents arising from this work.

Corresponding author

Correspondence to Aravind Asokan.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figs. 1–6 and Supplementary Tables 1–3

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.1599

Further reading